ArticleEplasty2024
Effects of Screening Hemoglobin A1C on Complications in Implant-Based Breast Reconstruction.
Article in Eplasty, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Many institutions have implemented universal hemoglobin A1c (HbA1c) screening for all preoperative patients in an effort to reduce rates of surgical complications. However, the usefulness of HbA1c screening for predicting complications after implant-based breast reconstruction has yet to be determined. The purpose of this study was to investigate the predictive value of HbA1c screening on postoperative complications following implant-based breast reconstruction. Methods: A retrospective cohort study of patients who underwent implant-based breast reconstruction at a single institution was conducted. All patients required an HbA1c screening preoperatively. Patients were categorized into 2 groups: normal HbA1c (<5.7%) or abnormal HbA1c (≥5.7%). The 2 groups were propensity score matched for baseline characteristics and compared for complication rates after the first- and second-stage procedures. Results: In this study, 203 patients who underwent first-stage breast reconstruction were divided into normal HbA1c (n = 135) and abnormal HbA1c (n = 68) cohorts. A propensity score weighted analysis demonstrated increased risk of incisional dehiscence in the abnormal group ( Conclusions: Patients with abnormal HbA1c on preoperative screening demonstrated higher rates of incisional dehiscence after first-stage breast reconstruction and higher rates of implant loss following second-stage breast reconstruction. Obtaining routine preoperative HbA1c screening should be considered as an adjunct to guide discussions about surgical risk for patients undergoing breast reconstruction.
Indexed as
Identifiers
40463921PMC12132407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.